Parkinson s disease Therapeutic strategies. Surat Tanprawate, MD Division of Neurology University of Chiang Mai
|
|
- Lynn Fletcher
- 6 years ago
- Views:
Transcription
1 Parkinson s disease Therapeutic strategies Surat Tanprawate, MD Division of Neurology University of Chiang Mai 1
2 Scope Modality of treatment Pathophysiology of PD and dopamine metabolism Drugs Are there guidelines for the treatment of Parkinson s disease? 2
3 Modality of treatment Symptoms base treatment Phamacologic VS Non-phamacologic Motor VS Non-motor symptom Neuro-protective treatment Reversing pathology Prevention 3
4 Signs and Symptoms of PD Tremor at rest "Pill rolling" Rigidity (stiffness) "lead pipe" or like a "cogwheel" Akinesia (inability to move) or Bradykinesia (slow movement) mask-like face, micrographia, freezing, impaired swallowing Postural instability with gait problems Motor symptoms (TRAP) 4
5 Non-Motor Symptoms Psychological depression, psychosis, anxiety, apathy, memory problems Sleep RLS, REM behavior disorder Autonomic Dysfunction constipation, drooling, decreased BP, temp regulation Others fatigue, speech, swallowing, seborrhea, pain, weight loss) 5
6 Pathophysiology of PD and dopamine metabolism 6
7 Neurotransmitters of the Basal Ganglia Inhibitory Excitatory Dopamine Norepinephrine Epinephrine GABA Acetylcholine Serotonin Histamine Glutamate 7
8 Symptoms of PD Dopamine Ach 8
9 Symptomatic Treatment Enhance dopaminergic transmission Drug manipulating neurotransmitter Dopamine Ach 9
10 10
11 Sites of action of common therapies for Parkinson s disease Tyrosine Tyrosine L-Dopa Dopamine DA MAO-B Levodopa Increases L-Dopa levels Selegeline Inhibits MAO-B DA Degradation Amantidine Stimulates release of DA Inhibits reuptake DA Agonists Bind to DA receptors Release Binding Reuptake Degradation COMT COMT Inhibitors Block degradation of DA and L-Dopa DA Receptors Parkinson s disease Acetylcholine Inhibitors Block action of ACh in striatum 11
12 Enhance Dopaminergic transmission DA precursor Administer DA agonists Ergolides Non- ergolides Direct or indirect potentiate dopaminergic transmission Enhance DA release Block DA reuptake Inhibit DA catabolism (degradation) 12
13 Increase DA synthesis Stimulate tyrosine hydroxylase (tetrahydrobiopterin) DA precursors (tyrosine, levodopa) Modify levodopa phamacokinetic Dietary modification (minimize AA intake, asminister antacids) Block peripheral dopa decarboxylase (carbidopa, benserazide) Slow-release levodopa (sinemet CR, Madopa HBS) 13
14 Enhance DA release Amantadine Methylphetamine Dextroamphetamine Pemoline Nicotine Electroconvulsive therapy Block DA reuptake Block DA reuptake Amantadine Tricyclics Bupropion Mazidol 14
15 Inhibit DA catabolism (degradation) COMT inhibition (Tolcapone, Entacapone) MAO-B inhibitors Depreny (seligiline) Administer DA agonist Administer DA agonist Bromocryptine Pergolide Lisuride Apomorphine Pramipexole Ropinirole Cabergolide 15
16 Drug manipulating other neurotransmitter Anti-cholinergic drugs Trihexyphenidyl(Artane) Benztropine(Cogentin) Biperidine(Akineton) Orphenadrine(Disipal) Procyclidine(Kemadrine) 16
17 How to management? When to started? Drug choice? Disease progression, management and complication of treatment 17
18 Stage
19 The Natural History of Response to Levodopa in Patients With Parkinson's Disease 19
20 When to started? Interfering with activities of daily living Patient to patient Job to job 20
21 21
22 Early-anti-PD therapy L-dopa VS Dopamine agonist 22
23 Levodopa Benefit Marked improvement in the major motor signs and symptoms Virtually all PD patients response May improve mortality rate Disadvantage Cause side effect Dyskinesia and dystonia Motor fluctuation Parkinsonian psychosis Do not treat all feature of PD Do not stop disease progression Theoretically: oxidative metabolites may accelerated disease progression 23
24 Dopamine agonist Benefit Anti parkinson effect when use as mono Rx or adjunctiove Rx Reduced risk for developing L-dopa related motor complication Do not generate oxidative metabolite Levodopa sparing effect Potential neuropotential effect Disadvantage Neuropsychiatric side effect Agonist specific side effect Sedative side effect Do not treat all feature of PD Do not stop disease progression 24
25 Elderly long-term complications of L-dopa therapy minimal: short live short-term side-effects of dopamine agonists high: comorbid L-dopa as the first-line Young patient risks VS benefits: L-dopa VS dopamine agonist drugs discuss age < 65, or age > 65 with no other co-morbidity are started on dopamine agonist as initial monotherapy 25
26 Dopamine agonist 26
27 Dopamine agonist 27
28 Dopamine agonist Drug Formulation,mg Starting dose, mg Bromocriptine 2.5, daily Target dose mg/d Pergolide 0.05, 0.25, daily Pramipexole 0.125, 0.25, 0.5, 1.0, 1.5 ropinirole 0.25, 0.5, 1.0, 2.0, twice daily twice daily
29 Dopamine agonist 29
30 Levodopa Levodopa + DDI Madopar (levodopa+benserazide) Sinemet (levodopa+carbidopa) Madopar HBS Sinemet CR 30
31 Doses of the preparations of Sinemet and Madopar 31
32 How should L-dopa be started? Gradually introduced L-dopa 100 mg/day is the traditional starting dose Madopar 62.5 twice daily, or Sinemet 62.5 twice daily. (Both of these tablet formulations contain 50 mg of L-dopa.) The daily dose of L-dopa should be increased by 100 mg after 1 week same amount after 2 weeks If tolerated, further increases should be reviewed after 6 12 weeks on this dose. 32
33 L-dopa side effect 33
34 34
35 COMT: early or late Advantages No titration: easy to administer Decrease off time, increase on time Enhanced motor responses in motor fluctuation patient Reduce risk of motor complication if used from onset of levodopa therapy Disadvantage Dopaminergic side effect, esp dyskinesia Discoloration of urine Tolcapone (peripheral+central COMT) Entacapone (peripheral COMT) 35
36 36
37 Anticholinergic drugs Advantage Some antiparkinsonian efficacy Peripheral acting agent may be useful to treating sialorrhea Disadvantage Relatively ineffective for the more disabling feature of PD Cognitive side effect Troublesome muscarinic side effect 37
38 MAO-B inhibitor (selegiline) Enhance the L-dopa effect May be neuroprotective property Start 5 mg twist daily 38
39 As the disease progress, the Therapeutic window narrow symptoms and side effects occur as the levodopa therapeutic window diminishes Dyskinesia threshold Efficacy threshold Smooth, extend response Absent or infrequent dyskinesia Diminished duration Increased incidence of dykinesia Short, unpredictable response on time is associared with dyskinesia 39
40 40
41 END Thank U 41
42 Overactive Microglial Cell NO Superoxide Free Radicals Proposed Mechanisms of Dopaminergic Neuron Death in Parkinson s Disease Unknown substance releases iron from storage molecules Mutation in mitochondrial gene Unknown toxin acts on mitochondrial protein Mitochondrial complex I inhibited Loss of mitochondrial funcion NO Superoxide More Free Radicals Free radicals cause cell damage Cell Death Fe Fe + Dopamine NO [Ca 2+ ] Dopamine- Producing Cell Overactive Glutamate- Producing Cell Glu Parkinson s disease 42
Pharmacologic Treatment of Parkinson s Disease. Nicholas J. Silvestri, M.D. Assistant Professor of Neurology
+ Pharmacologic Treatment of Parkinson s Disease Nicholas J. Silvestri, M.D. Assistant Professor of Neurology + Overview n Brief review of Parkinson s disease (PD) n Clinical manifestations n Pathophysiology
More informationPharmacologic Treatment of Parkinson s Disease. Nicholas J. Silvestri, M.D. Associate Professor of Neurology
+ Pharmacologic Treatment of Parkinson s Disease Nicholas J. Silvestri, M.D. Associate Professor of Neurology + Disclosures n NO SIGNIFICANT FINANCIAL, GENERAL, OR OBLIGATION INTERESTS TO REPORT + Learning
More informationDrug Therapy of Parkinsonism. Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia
Drug Therapy of Parkinsonism Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia Parkinsonism is a progressive neurological disorder of muscle movement, usually
More informationParkinson s Disease. Sirilak yimcharoen
Parkinson s Disease Sirilak yimcharoen EPIDEMIOLOGY ~1% of people over 55 years Age range 35 85 years peak age of onset is in the early 60s ~5% of cases characterized by an earlier age of onset (typically
More information10th Medicine Review Course st July Prakash Kumar
10th Medicine Review Course 2018 21 st July 2018 Drug Therapy for Parkinson's disease Prakash Kumar National Neuroscience Institute Singapore General Hospital Sengkang General Hospital Singhealth Duke-NUS
More informationScott J Sherman MD, PhD The University of Arizona PARKINSON DISEASE
Scott J Sherman MD, PhD The University of Arizona PARKINSON DISEASE LEARNING OBJECTIVES The Course Participant will: 1. Be familiar with the pathogenesis of Parkinson s Disease (PD) 2. Understand clinical
More informationDRUG TREATMENT OF PARKINSON S DISEASE. Mr. D.Raju, M.pharm, Lecturer
DRUG TREATMENT OF PARKINSON S DISEASE Mr. D.Raju, M.pharm, Lecturer PARKINSON S DISEASE (parkinsonism) is a neurodegenerative disorder which affects t h e b a s a l g a n g l i a - and is associated with
More informationParkinson s Disease Current Treatment Options
Parkinson s Disease Current Treatment Options Daniel Kassicieh, D.O., FAAN Sarasota Neurology, P.A. PD: A Chronic Neurodegenerative Ds. 1 Million in USA Epidemiology 50,000 New Cases per Year Majority
More informationDrugs used in Parkinsonism
Drugs used in Parkinsonism قادة فريق علم األدوية : لي التميمي & عبدالرحمن ذكري الشكر موصول ألعضاء الفريق املتميزين : جومانة القحطاني ندى الصومالي روان سعد القحطاني pharma436@outlook.com @pharma436 Your
More informationTreatment of Parkinson s Disease and of Spasticity. Satpal Singh Pharmacology and Toxicology 3223 JSMBS
Treatment of Parkinson s Disease and of Spasticity Satpal Singh Pharmacology and Toxicology 3223 JSMBS singhs@buffalo.edu 716-829-2453 1 Disclosures NO SIGNIFICANT FINANCIAL, GENERAL, OR OBLIGATION INTERESTS
More informationparts of the gastrointenstinal tract. At the end of April 2008, it was temporarily withdrawn from the US Market because of problems related to
parts of the gastrointenstinal tract. At the end of April 2008, it was temporarily withdrawn from the US Market because of problems related to crystallization of the drug, which caused unreliable drug
More informationPARKINSON S DISEASE. Nigrostriatal Dopaminergic Neurons 5/11/16 CARDINAL FEATURES OF PARKINSON S DISEASE. Parkinson s disease
5/11/16 PARKINSON S DISEASE Parkinson s disease Prevalence increases with age (starts 40s60s) Seen in all ethnic groups, M:F about 1.5:1 Second most common neurodegenerative disease Genetics role greater
More informationHistory Parkinson`s disease. Parkinson's disease was first formally described in 1817 by a London physician named James Parkinson
Parkinsonismm History Parkinson`s disease Parkinson's disease was first formally described in 1817 by a London physician named James Parkinson Definition : Parkinsonism: Parkinsonism is a progressive neurological
More information2-The age at onset of PD is variable, usually between 50 and 80 years, with a mean onset of 55 years (1).
Parkinson Disease 1-Parkinson disease (PD) is a chronic, progressive movement disorder resulting from loss of dopamine from the nigrostriatal tracts in the brain, and is characterized by rigidity, bradykinesia,
More informationParkinson s Disease Medications: Professionals Edition
Parkinson s Disease Clinic and Research Center University of California, San Francisco 505 Parnassus Ave., Rm. 795-M, Box 0114 San Francisco, CA 94143-0114 (415) 476-9276 http://pdcenter.neurology.ucsf.edu
More informationMovement Disorders: A Brief Overview
Movement Disorders: A Brief Overview Albert Hung, MD, PhD Massachusetts General Hospital Harvard Medical School August 17, 2006 Cardinal Features of Parkinsonism Tremor Rigidity Bradykinesia Postural imbalance
More informationTreatment of Parkinson s Disease: Present and Future
Treatment of Parkinson s Disease: Present and Future Karen Blindauer, MD Professor of Neurology Director of Movement Disorders Program Medical College of Wisconsin Neuropathology: Loss of Dopamine- Producing
More informationMedications used to treat Parkinson s disease
Medications used to treat Parkinson s disease Edwin B. George, M.D., Ph.D. Director of Wayne State University Movement Disorder Clinic University Health Center Neurology Clinic University Health The John
More informationThe Shaking Palsy of 1817
The Shaking Palsy of 1817 A Treatment Update on Parkinson s Disease Dr Eitzaz Sadiq Neurologist CH Baragwanath Acadamic Hospital Parkinson s Disease O Premature death of dopaminergic neurons O Symptoms
More informationMotor Fluctuations Stephen Grill, MD, PHD Parkinson s and Movement Disorders Center of Maryland and Johns Hopkins University
Motor Fluctuations Stephen Grill, MD, PHD Parkinson s and Movement Disorders Center of Maryland and Johns Hopkins University I have no financial interest with any entity producing marketing, re-selling,
More informationOptimizing Clinical Communication in Parkinson s Disease:
Optimizing Clinical Communication in Parkinson s Disease:,Strategies for improving communication between you and your neurologist PFNCA Symposium March 25, 2017 Pritha Ghosh, MD Assistant Professor of
More informationDrug Management of Parkinsonism. By Prof. Mohammad Saleh M. Hassan PhD. (Pharma); MSc. (Ped.); MHPE (Ed.)
Drug Management of Parkinsonism By Prof. Mohammad Saleh M. Hassan PhD. (Pharma); MSc. (Ped.); MHPE (Ed.) Drug management of Parkinsonism Levodopa Ergot derivatives noamine Oxidaes Inhibitors Catechol-Omethyl
More informationPARKINSON S MEDICATION
PARKINSON S MEDICATION History 1940 50 s Neurosurgeons operated on basal ganglia. Improved symptoms. 12% mortality 1960 s: Researchers identified low levels of dopamine caused Parkinson s leading to development
More informationBest Medical Treatments for Parkinson s disease
Best Medical Treatments for Parkinson s disease Bernadette Schöneburg, M.D. June 20 th, 2015 What is Parkinson s Disease (PD)? Progressive neurologic disorder that results from the loss of specific cells
More informationParkinson s Disease. Patients will ask you. 8/14/2015. Objectives
Parkinson s Disease Jean Van Kingsley MS, FNP-BC Objectives Describe the pathophysiolgy of PD. Review clinical charachteristics of PD. Identify management strategies, to maximize functional status. Recognize
More informationEvaluation and Management of Parkinson s Disease in the Older Patient
Evaluation and Management of Parkinson s Disease in the Older Patient David A. Hinkle, MD, PhD Comprehensive Movement Disorders Clinic Pittsburgh Institute for Neurodegenerative Diseases University of
More informationDr Barry Snow. Neurologist Auckland District Health Board
Dr Barry Snow Neurologist Auckland District Health Board Dystonia and Parkinson s disease Barry Snow Gowers 1888: Tetanoid chorea Dystonia a movement disorder characterized by sustained or intermittent
More informationRecent Advances in the cause and treatment of Parkinson disease. Anthony Schapira Head of Dept. Clinical Neurosciences UCL Institute of Neurology UCL
Recent Advances in the cause and treatment of Parkinson disease Anthony Schapira Head of Dept. Clinical Neurosciences UCL Institute of Neurology UCL SOME BACKGROUND incidence rate (per 100.000 person years)
More information475 GERIATRIC PSYCHOPHARMACOLOGY (p.1)
475 GERIATRIC PSYCHOPHARMACOLOGY (p.1) I. General Information? Use lower doses? Start low and go slow? Expect prolonged elimination ½ lives? Expect sedative-hypnotics to be dementing, to impair cognitive
More informationPD: Key Treatment Considerations
PD: Key Treatment Considerations 2018 Management of Neurologic and Neurosurgical Disorders in Daily Practice Elise Anderson MD Medical Co-Director, PBSI Movement Disorders 11/27/2018 1 Outline Treatment
More informationKey Concepts and Issues in Parkinson s Disease in 2016
Key Concepts and Issues in Parkinson s Disease in 2016 Michael Rezak, M.D., Ph.D. Section Chief, Neurosciences Institute Director, Movement Disorders and Neurodegenerative Diseases Center Northwestern
More informationRe-Submission. Scottish Medicines Consortium. rasagiline 1mg tablet (Azilect ) (No. 255/06) Lundbeck Ltd / Teva Pharmaceuticals Ltd.
Scottish Medicines Consortium Re-Submission rasagiline 1mg tablet (Azilect ) (No. 255/06) Lundbeck Ltd / Teva Pharmaceuticals Ltd 10 November 2006 The Scottish Medicines Consortium (SMC) has completed
More information05-Nov-15. Impact of Parkinson s Disease in Australia. The Nature of Parkinson s disease 21st Century
Peter Silburn Professor Clinical Neuroscience University of Queensland Queensland Brain Institute Neurosciences Queensland Impact of in Australia Second most common neurodegenerative disorder Up to 64,000
More informationCardinal Features of Parkinson s. Management of Parkinson s Disease. Drug Induced Parkinson s. Other Parkinson s Symptoms.
Cardinal Features of Parkinson s Management of Parkinson s Disease Kristin S. Meyer, PharmD, CGP, FASHP Assistant Professor of Pharmacy Practice Drake University & Iowa Veterans Home Spring 2009 Tremor
More informationMedication Management & Strategies When the levodopa honeymoon is over
Medication Management & Strategies When the levodopa honeymoon is over Eric J Pappert, MD Parkinson s Disease & Movement Disorders Center Neurology Associates Medication Options in Parkinson s Carbidopa/Levodopa
More informationParkinson's Disease. Robert L. Copeland, Ph.D. Howard University College of Medicine Department of Pharmacology
Parkinson's Disease Robert L. Copeland, Ph.D. Howard University College of Medicine Department of Pharmacology 18 February 2002 Parkinson Disease Neurological disease affecting over four million patients
More informationParkinson s Disease Update
Parkinson s Disease Update Elise Anderson MD Providence Center for Parkinson s Disease October 26, 2017 11/6/2017 1 Disclosures GE Speaker, DaTSCAN 11/6/2017 2 Outline PD diagnosis Motor and nonmotor symptoms
More informationASHI691: Why We Fall Apart: The Neuroscience and Neurophysiology of Aging. Dr. Olav E. Krigolson Lecture 5: PARKINSONS DISEASE
ASHI691: Why We Fall Apart: The Neuroscience and Neurophysiology of Aging Dr. Olav E. Krigolson krigolson@uvic.ca Lecture 5: PARKINSONS DISEASE The Basal Ganglia Primary motor cortex Execution of movement
More information8/28/2017. Behind the Scenes of Parkinson s Disease
BEHIND THE SCENCES IN Parkinson s Disease Behind the Scenes of Parkinson s Disease Anna Marie Wellins DNP, ANP C Objectives Describe prevalence of Parkinson's disease (PD) Describe the hallmark pathologic
More informationPresented by Meagan Koepnick, Josh McDonald, Abby Narayan, Jared Szabo Mentored by Dr. Doorn
Presented by Meagan Koepnick, Josh McDonald, Abby Narayan, Jared Szabo Mentored by Dr. Doorn Objectives What agents do we currently have available and what do we ideally need? What biomarkers exist for
More informationCE on SUNDAY Newark, NJ October 18, 2009
CE on SUNDAY Newark, NJ October 18, 2009 Date: Sunday, October 18, 2009 Time: 10:30 AM 11:45 AM Location: Sheraton Newark Airport Hotel Title: Speaker(s): Treating Parkinson s Disease: A Pharmacist s Overview
More informationParkinson s Pharmacology
PHPP 517 (IT-III) Fall 2011 JACOBS Wed 10/12 8:00 8:50 AM 1 Learning objectives 1. Describe the direct and indirect pathways of the extrapyramidal system and its modulation by ACh and DA. 2. Contrast the
More informationObjectives. Emerging Treatments in Parkinson s s Disease. Pathology. As Parkinson s progresses it eventually affects large portions of the brain.
Objectives Emerging Treatments in Parkinson s s Disease 1) Describe recent developments in the therapies for Parkinson s Disease Jeff Kraakevik MD Assistant Professor OHSU/Portland VAMC Parkinson s Center
More informationParkinson's Disease KP Update
Parkinson's Disease KP Update Andrew Imbus, PA-C Neurology, Movement Disorders Kaiser Permanente, Los Angeles Medical Center No disclosures "I often say now I don't have any choice whether or not I have
More informationMargo J Nell Dept Pharmacology
Margo J Nell Dept Pharmacology 1 The extra pyramidal system Separation of cortico-spinal system (pyramidal system, (PS)) from the basal ganglia (extra pyramidal motor system (EPS)) because they produce
More informationClinical Features and Treatment of Parkinson s Disease
Clinical Features and Treatment of Parkinson s Disease Richard Camicioli, MD, FRCPC Cognitive and Movement Disorders Department of Medicine University of Alberta 1 Objectives To review the diagnosis and
More informationParkinson s Disease Update. Colleen Peach, RN, MSN, FNP Movement Disorders Clinic Emory University School of Medicine March 7, 2015
Parkinson s Disease Update Colleen Peach, RN, MSN, FNP Movement Disorders Clinic Emory University School of Medicine March 7, 2015 Parkinson s Disease Progressive, chronic, neurodegenerative disease Slow,
More informationParkinson s Disease Update. Presented by Joanna O Leary, MD Movement disorder neurologist Providence St. Vincent s
Parkinson s Disease Update Presented by Joanna O Leary, MD Movement disorder neurologist Providence St. Vincent s What is a movement disorder? Neurological disorders that affect ability to move by causing
More informationEvaluation of Parkinson s Patients and Primary Care Providers
Evaluation of Parkinson s Patients and Primary Care Providers 2018 Movement Disorders Half Day Symposium Elise Anderson MD Medical Co-Director, PBSI Movement Disorders 6/28/2018 1 Disclosures GE Speaker,
More informationThe symptoms of the Parkinson s disease may vary from person to person. The symptoms might include the following:
1 PARKINSON S DISEASE Parkinson's disease is a long term disease related to the central nervous system that mainly affects the motor system, resulting in the loss of dopamine, which helps in producing
More informationTRANSPARENCY COMMITTEE OPINION. 18 March 2009
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 18 March 2009 REQUIP LP 2 mg extended-release tablet Box of 21 tablets (CIP: 379 214-8) Box of 28 tablets (CIP: 379
More informationWHAT DEFINES YOPD? HANDLING UNIQUE CONCERNS REBECCA GILBERT, MD, PHD VICE PRESIDENT, CHIEF SCIENTIFIC OFFICER, APDA MARCH 14, 2019
WHAT DEFINES YOPD? HANDLING UNIQUE CONCERNS REBECCA GILBERT, MD, PHD VICE PRESIDENT, CHIEF SCIENTIFIC OFFICER, APDA MARCH 14, 2019 YOUNG ONSET PARKINSON S DISEASE Definition: Parkinson s disease diagnosed
More informationANTIPARKINSONIAN DRUGS. DRUGs ACT ON CNS (Pharmacology) Unit-5(8)
ANTIPARKINSONIAN DRUGS DRUGs ACT ON CNS (Pharmacology) Unit-5(8) Parkinsonism (PD) Extrapyramidal motor function disorder characterized by Rigidity Tremor Hypokinesia/Bradykinesia Impairment of postural
More informationNovel approaches to the pharmacological treatment of Parkinson s disease. Peter Jenner King s College UK
Novel approaches to the pharmacological treatment of Parkinson s disease Peter Jenner King s College UK Disclosures and Disclaimers Speakers fees and consultancy fees have been received from Britannia
More informationPrior Authorization with Quantity Limit Program Summary
Gocovri (amantadine) Prior Authorization with Quantity Limit Program Summary This prior authorization applies to Commercial, NetResults A series, SourceRx and Health Insurance Marketplace formularies.
More informationParkinson Disease. Lorraine Kalia, MD, PhD, FRCPC. Presented by: Ontario s Geriatric Steering Committee
Parkinson Disease Lorraine Kalia, MD, PhD, FRCPC Key Learnings Parkinson Disease (L. Kalia) Key Learnings Parkinson disease is the most common but not the only cause of parkinsonism Parkinson disease is
More information2/20/18. History of Parkinson s. What is happening in the brain? DOPAMINE! Epidemiology. Parkinson s Disease. It s much more than tremor
Parkinson s Disease History of Parkinson s It s much more than tremor Laura Dixon, DNP, MPA, APRN, FNP-BC University of Louisville Department of Neurology Movement Disorders Division Parkinson s Disease
More informationXADAGO (safinamide) oral tablet
XADAGO (safinamide) oral tablet Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Pharmacy Coverage
More informationParkinson s Disease WHERE HAVE WE BEEN, WHERE ARE WE HEADING? CHARLECE HUGHES D.O.
Parkinson s Disease WHERE HAVE WE BEEN, WHERE ARE WE HEADING? CHARLECE HUGHES D.O. Parkinson s Epidemiology AFFECTS 1% OF POPULATION OVER 65 MEAN AGE OF ONSET 65 MEN:WOMEN 1.5:1 IDIOPATHIC:HEREDITARY 90:10
More informationParkinson's Disease and how you can make a difference with medication
Parkinson's Disease and how you can make a difference with medication Alyson Franks Parkinson's and Movement Disorder Nurse Specialist Royal Hallamshire Hospital No treatment all Complementary Therapy
More informationParkinson s Disease: initial diagnosis, initial treatment & non-motor features. J. Timothy Greenamyre, MD, PhD
Parkinson s Disease: initial diagnosis, initial treatment & non-motor features J. Timothy Greenamyre, MD, PhD Involuntary tremulous motion, with lessened muscular power, in parts not in action and even
More informationThe PD You Don t See: Cognitive and Non-motor Symptoms
The PD You Don t See: Cognitive and Non-motor Symptoms Benzi M. Kluger, M.D., M.S. Associate Professor of Neurology and Psychiatry Director Movement Disorders Center University of Colorado Denver Goals
More informationCommunicating About OFF Episodes With Your Doctor
Communicating About OFF Episodes With Your Doctor Early in Parkinson s disease (PD), treatment with levodopa and other anti-pd drugs provides continuous benefit. As the disease progresses, however, symptom
More informationPD ExpertBriefings: Parkinson s Medications: Today and Tomorrow Led By: Cynthia L. Comella, M.D., F.A.A.N.
PD ExpertBriefings: Parkinson s Medications: Today and Tomorrow Led By: Cynthia L. Comella, M.D., F.A.A.N. To hear the session live on: Tuesday, April 17, 2012 at 1:00 PM ET. DIAL: 1 (888) 272-8710 and
More informationIssues for Patient Discussion
onmotor complications radykinesia Screening Tools asked PD micrographia eurodegeneration Designed for Use by Family Practitioners remor on-off opamine agonists tiffness depression ostural instability wearing
More informationParkinson s Disease in the Elderly A Physicians perspective. Dr John Coyle
Parkinson s Disease in the Elderly A Physicians perspective Dr John Coyle Overview Introduction Epidemiology and aetiology Pathogenesis Diagnosis and clinical features Treatment Psychological issues/ non
More informationPARKINSON S PRIMER. Dr. Kathryn Giles MD, MSc, FRCPC Cambridge, Ontario, Canada
PARKINSON S PRIMER Dr. Kathryn Giles MD, MSc, FRCPC Cambridge, Ontario, Canada COPYRIGHT 2017 BY SEA COURSES INC. All rights reserved. No part of this document may be reproduced, copied, stored, or transmitted
More informationParkinson s Disease. Gillian Sare
Parkinson s Disease Gillian Sare Outline Reminder about PD Parkinson s disease in the inpatient Surgical patients with PD Patients who cannot swallow End of life care Parkinson s disease PD is the second
More informationMaking Every Little Bit Count: Parkinson s Disease. SHP Neurobiology of Development and Disease
Making Every Little Bit Count: Parkinson s Disease SHP Neurobiology of Development and Disease Parkinson s Disease Initially described symptomatically by Dr. James Parkinson in 1817 in An Essay on the
More informationDRUGS THAT ACT IN THE CNS
DRUGS THAT ACT IN THE CNS Drugs for Neurodegenerative Diseases 2 Dr Karamallah S. Mahmood PhD Clinical Pharmacology 1 DRUGS USED IN PARKINSON S DISEASE/ B. Selegiline and rasagiline Selegiline, also called
More informationFirst described by James Parkinson in his classic 1817 monograph, "An Essay on the Shaking Palsy"
Parkinson's Disease First described by James Parkinson in his classic 1817 monograph, "An Essay on the Shaking Palsy" Parkinson s disease (PD) is a neurological disorder characterized by a progressive
More informationWith Time, The Pathology of PD Spreads Throughout the Brain
With Time, The Pathology of PD Spreads Throughout the Brain Braak s staging of Parkinson s disease pathology dm co sn mc hc fc 1 Hubert H. Fernandez, MD, FAAN Professor of Medicine (Neurology) Cleveland
More informationParkinsonism or Parkinson s Disease I. Symptoms: Main disorder of movement. Named after, an English physician who described the then known, in 1817.
Parkinsonism or Parkinson s Disease I. Symptoms: Main disorder of movement. Named after, an English physician who described the then known, in 1817. Four (4) hallmark clinical signs: 1) Tremor: (Note -
More informationACUTE MANAGEMENT OF PARKINSON S PATIENTS WHO ARE NIL BY MOUTH (NBM) OR WHO HAVE A COMPROMISED SWALLOW NHS LANARKSHIRE PARKINSON S TEAM
ACUTE MANAGEMENT OF PARKINSON S PATIENTS WHO ARE NIL BY MOUTH (NBM) OR WHO HAVE A COMPROMISED SWALLOW NHS LANARKSHIRE PARKINSON S TEAM 1 CONTENTS: TOPIC PAGE Introduction 3 What should you do when a PD
More informationProgram Highlights. Michael Pourfar, MD Co-Director, Center for Neuromodulation New York University Langone Medical Center New York, New York
Program Highlights David Swope, MD Associate Professor of Neurology Mount Sinai Health System New York, New York Michael Pourfar, MD Co-Director, Center for Neuromodulation New York University Langone
More informationMovement Disorders. Eric Kraus, MD! Neurology!
Movement Disorders Eric Kraus, MD! Neurology! Classify Bradykinesia! Tic! Myoclonus! Tremor! Dystonia! Athetosis! Chorea! Ballismus! Case 1 This 64 year-old female has had progression of a tremor over
More informationParkinson s disease. Information for patients and carers. The Leeds Teaching Hospitals NHS Trust
n The Leeds Teaching Hospitals NHS Trust Parkinson s disease Information for patients and carers in partnership with Leeds Community Healthcare NHS Trust The symptoms of Parkinson s appear when the levels
More informationTHE ART OF MEDICATION MANAGEMENT IN PARKINSON S DISEASE
THE ART OF MEDICATION MANAGEMENT IN PARKINSON S DISEASE J O N AT H A N S Q U I R E S, M D, F R C P C C L I N I C A L I N S T R U C T O R, UBC F AC U L T Y O F M E D I C I N E P AC I F I C P AR K I N S
More informationIII./3.1. Movement disorders with akinetic rigid symptoms
III./3.1. Movement disorders with akinetic rigid symptoms III./3.1.1. Parkinson s disease Parkinson s disease (PD) is the second most common neurodegenerative disorder worldwide after Alzheimer s disease.
More informationWhat s new for diagnosing and treating Parkinson s Disease?
What s new for diagnosing and treating Parkinson s Disease? Erika Driver-Dunckley, MD Associate Professor of Neurology Program Director Movement Disorders Fellowship Assistant Program Director Neurology
More informationEnhanced Primary Care Pathway: Parkinson s Disease
Enhanced Primary Care Pathway: Parkinson s Disease 1. Focused summary of PD relevant to primary care Parkinson s Disease (PD) and Essential tremor (ET) are two of the most common movement disorders encountered
More informationVisualization and simulated animations of pathology and symptoms of Parkinson s disease
Visualization and simulated animations of pathology and symptoms of Parkinson s disease Prof. Yifan HAN Email: bctycan@ust.hk 1. Introduction 2. Biochemistry of Parkinson s disease 3. Course Design 4.
More informationLecture 5 Skeletal muscle relaxants. Pharmacologic management of parkinsonism and other movement disorders.
Lecture 5 Skeletal muscle relaxants. Pharmacologic management of parkinsonism and other movement disorders. I. SKELETAL MUSCLE RELAXANTS Skeletal muscle relaxants are pharmacologically active substances
More informationRasagiline and Rapid Symptomatic Motor Effect in Parkinson s Disease: Review of Literature
Neurol Ther (2014) 3:41 66 DOI 10.1007/s40120-013-0014-1 REVIEW Rasagiline and Rapid Symptomatic Motor Effect in Parkinson s Disease: Review of Literature Michele Pistacchi Francesco Martinello Manuela
More informationAdvanced Therapies for Motor Symptoms in PD. Matthew Boyce MD
Advanced Therapies for Motor Symptoms in PD Matthew Boyce MD Medtronic Education Teva Speakers Bureau Acadia Speakers Bureau Disclosures Discuss issues in advanced PD Adjunct therapies to levo-dopa Newer
More informationWelcome and Introductions
Parkinson s Disease Spotlight on Treatment Advances Tuesday, January 26, 2016 Welcome and Introductions Stephanie Paul Vice President Development and Marketing American Parkinson Disease Association 1
More informationNew Medicines Committee Briefing July 2011
New Medicines Committee Briefing July 2011 Pramipexole immediate-release (Mirapexin ) and Pramipexole modifiedrelease (Mirapexin prolonged release) for the treatment of Parkinson s Disease Pramipexole
More informationChapter 20. Media Directory. Amyotrophic Lateral Sclerosis. Alzheimer s Disease. Huntington s Chorea. Multiple Sclerosis
Chapter 20 Drugs for Degenerative Diseases of the Nervous System Slide 18 Media Directory Levadopa Animation Upper Saddle River, New Jersey 07458 All rights reserved. Alzheimer s Disease Amyotrophic Lateral
More informationParkinson s disease: diagnosis and current management
n DRUG REVIEW Parkinson s disease: diagnosis and current management Lucy Collins MPhil, Gemma Cummins MRCPI and Roger A Barker PhD, MRCP SPL Treatment for Parkinson s should be tailored to the needs of
More informationSemivoluntary movement (=unvoluntary)
EXTRAPYRAMIDAL DISORDERS = Movement disorders = Degenerative disease 1 4 types of movements: Voluntary movement Semivoluntary movement (=unvoluntary) Involuntary movement Automatic movement 2 3 Movement
More informationNeurodegenerative diseases
Neurodegenerative diseases Hiwa K. Saaed, PhD Department of Pharmacology & Toxicology College of Pharmacy University of Sulaimani Hiwa.saaed@univsul.edu.iq 2018-19 Neurodegenerative diseases of the CNS
More informationPharmacological treatment of Parkinson's disease
Pharmacological treatment of Parkinson's disease Joaquim Ferreira, MD, PhD Laboratory of Clinical Pharmacology and Therapeutics Faculty of Medicine University of Lisbon PD PROGRESSION DISABILITY instability
More informationParkinson s Disease. Graham A. Glass, MD. Assistant Professor of Neurology University of California San Francisco
Parkinson s Disease Graham A. Glass, MD Assistant Professor of Neurology University of California San Francisco San Francisco VA Medical Center Parkinson s Disease Research, Education and Clinical Center
More informationPal Riba, M.D., Ph.D. Department of Pharmacology and Pharmacotherapy Semmelweis University, Budapest, Hungary November 7, 2017
Pal Riba, M.D., Ph.D. Department of Pharmacology and Pharmacotherapy Semmelweis University, Budapest, Hungary November 7, 2017 Definition of neurodegeneration Irreversible death of neurons resulting in
More informationNeurodegenerative Disease. April 12, Cunningham. Department of Neurosciences
Neurodegenerative Disease April 12, 2017 Cunningham Department of Neurosciences NEURODEGENERATIVE DISEASE Any of a group of hereditary and sporadic conditions characterized by progressive dysfunction,
More informationAnticholinergics. COMT* Inhibitors. Dopaminergic Agents. Dopamine Agonists. Combination Product
Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35, Salem, Oregon 97301-1079 Phone 503-945-5220 Fax 503-947-1119 Class Update: Parkinson s Drugs Month/Year of Review:
More informationScottish Medicines Consortium
Scottish Medicines Consortium rotigotine 2mg/24 hours, 4mg/24 hours, 6mg/24 hours, 8mg/24 hours transdermal patch (Neupro ) (No: 289/06) Schwarz Pharma Ltd. 7 July 2006 The Scottish Medicines Consortium
More informationDrug treatment of early Parkinson s disease (motor symptoms)
5 Drug treatment of early Parkinson s disease (motor symptoms) 5.1 When should treatment be started for a patient with Parkinson s disease? 67 5.2 Are there guidelines for the treatment of Parkinson s
More informationUnderstanding Parkinson s Disease Important information for you and your loved ones
Patient Education Understanding Parkinson s Disease Important information for you and your loved ones This handout explains the signs, symptoms, and possible treatments of Parkinson s disease. Parkinson
More informationPharmacy Coverage Guidelines are subject to change as new information becomes available.
ZELAPAR (selegiline hydrochloride) orally disintegrating tablet Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific
More information